Top Qs
Timeline
Chat
Perspective
MMAI
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
5-Methoxy-6-methyl-2-aminoindane (MMAI) is a drug of the 2-aminoindane group developed in the 1990s by a team led by David E. Nichols at Purdue University.[1] It acts as a less neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogenic effects in humans.[1][2][3][4] It has been sold as a designer drug and research chemical online since 2010.
The drug is one of the only known monoamine releasing agents (MRAs) with greater than 100-fold selectivity for the serotonin transporter (SERT) over the dopamine transporter (DAT).[5] Receptor interaction data for MMAI have also been reported.[6][7]
MMAI has been shown to relieve stress-induced depression in rats more robustly than sertraline,[8] and as a result it has been suggested that SSRAs like MMAI and 4-methylthioamphetamine (4-MTA) could be developed as novel antidepressants with a faster onset of therapeutic action and superior effectiveness to current antidepressants such as the selective serotonin reuptake inhibitors (SSRIs).[9]
MMAI alone does not appear to produce serotonergic neurotoxicity with either acute or chronic administration in animals.[10][11] However, subsequent research found that a single high dose of MMAI could produce significant serotonergic neurotoxicity.[10][11] In addition, combination of MMAI with the dopamine releasing agent dextroamphetamine has been found to produce dose-dependent serotonergic neurotoxicity in animals.[10] Hence, MMAI is not a fully non-neurotoxic MDMA analogue.[10][11]
MMAI is the 2-aminoindane analogue of 3-methoxy-4-methylamphetamine (MMA).[12][3]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads